<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787239</url>
  </required_header>
  <id_info>
    <org_study_id>HLX01-NHL03</org_study_id>
    <nct_id>NCT02787239</nct_id>
  </id_info>
  <brief_title>Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <brief_summary>
    <textblock>
      Multicenter, Randomized, Double-blind, Parallel, Phase III Clinical Study to Compare the
      Efficacy and Safety of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in
      Previously Untreated Subjects With CD20+ DLBCL
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Objective Response Rate (ORR)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>B-cell Non Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>HLX01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX01</intervention_name>
    <arm_group_label>HLX01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP</intervention_name>
    <arm_group_label>HLX01</arm_group_label>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated CD20-positive DLBCL confirmed.

          -  IPI score of 1 to 2, Stage I ~ IV, Score 0 needs to accompanied by bulky disease,
             which is defined as the presence of a tumor mass with a diameter of more than 7.5 cm.

          -  ECOG performance status of 0 to 2.

          -  More than 6 months life expectancy.

          -  At least one measurable lesion: For nodal tumor mass, more than 1.5 cm in the long
             axis and more than 1.0 cm in the short axis; For extranodal tumor mass, more than 1.0
             cm in the long axis.

          -  18 years to 70 years; Male or female patients.

        Exclusion Criteria:

          -  Known allergic reactions against human or murine monoclonal antibody, murine products,
             or foreign proteins.

          -  Known allergic reactions against any component of CHOP regimen.

          -  Previous treatment for NHL, including chemotherapy, immunotherapy, partial
             radiotherapy for lymphoma, monoclonal antibody therapy or surgical treatment
             (excluding lymph node biopsies and surgical resection for non-lymphoma lesions).

          -  History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for
             other disease (e.g., rheumatoid arthritis).

          -  Prior use of any monoclonal antibody within 3 months.

          -  Primary central nervous system(CNS) lymphoma, secondary CNS involvement, grey zone
             lymphoma (GZL) between burkitt and DLBCL, primary effusion lymphoma, plasmablastic
             lymphoma, primary cutaneous DLBCL, anaplastic lymphoma kinase(ALK) positive DLBCL or
             transformed lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

